In the time that has passed since SLAS2022 in Boston, USA, the drug discovery industry has had to deal with all manner of external obstacles, from the war in Ukraine, to how Brexit has changed the world’s relationship with the UK, and the post-Covid-19 catch-up now that vaccines have rolled out internationally. Yet, the overarching outlook for SLAS2023, taking place from February 25 – March 1, 2023 in San Diego, USA, appears to be a very optimistic one, with the Innovation Accelerated theme showcasing the sector’s get-up-and-go attitude.
While companies make these commitments and partner for a better future, others shared successes in 2022. Using AI, researchers at Chalmers University of Technology, Sweden succeeded in designing synthetic DNA that controls the cells’ protein production. Meanwhile, Poolbeg Pharma and OneThree Biotech have discovered novel drug targets for the treatment of respiratory syncytial virus (RSV) using an AI programme.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
